» Articles » PMID: 27155210

Acute Exacerbations of Chronic Obstructive Pulmonary Disease with Low Serum Procalcitonin Values Do Not Benefit from Antibiotic Treatment: a Prospective Randomized Controlled Trial

Overview
Publisher Elsevier
Date 2016 May 8
PMID 27155210
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The majority of patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) have low serum procalcitonin (PCT) values. The aim of this study was to determine whether these patients may benefit from antibiotic treatment.

Methods: A total of 457 patients with AECOPD were screened; 194 patients with AECOPD and PCT <0.1 ng/ml were assigned randomly to an antibiotic group or a control group. In the per-protocol (PP) population, the antibiotic group subjects were required to have used antibiotics for at least 3 days, and the control group subjects were required not to have used antibiotics within the 10 days after admission. The intention-to-treat (ITT) population was defined as the patients who were randomized. The primary outcome was the treatment success rate on day 10 after admission. Secondary outcomes were symptoms assessed on a visual analog scale (VAS), length of hospitalization, mortality, exacerbation rate, and re-hospitalization within 30 days of follow-up (study registered at chictr.org.cn: ChiCTR-TRC-14004726).

Results: 95 patients in the antibiotic group and 96 patients in the control group completed the study. In the ITT population, the overall treatment success rate in the control group (95.8%) was similar to that in the antibiotic group (93.7%), with no significant difference (p=0.732). Five patients in the antibiotic group died, either in hospital or within 30 days of discharge. In the control group, two died within 30 days of discharge. Antibiotic use in the control group was 17.7% (17/96), and age ≥75 years was a predictive risk factor for requiring antibiotic therapy in the control group (odds ratio 4.055, 95% confidence interval 1.297-12.678; p=0.012). According to the PP analysis, the treatment success rate on day 10 after admission was 98.7% (78/79) in the control group and 93.7% (89/95) in the antibiotic group, also with no significant difference (p=0.193). No secondary outcome was significantly different between the two groups.

Conclusion: Antibiotic treatment is no better than placebo in AECOPD with a PCT level <0.1 ng/ml.

Citing Articles

Utility of Procalcitonin in Clinical Practice.

Auron M, Seymann G J Brown Hosp Med. 2025; 2(3):81280.

PMID: 40026457 PMC: 11864458. DOI: 10.56305/001c.81280.


The Saudi Thoracic Society Evidence-based guidelines for the diagnosis and management of chronic obstructive pulmonary disease.

Al-Jahdali H, Al-Lehebi R, Lababidi H, Alhejaili F, Habis Y, Alsowayan W Ann Thorac Med. 2025; 20(1):1-35.

PMID: 39926399 PMC: 11804957. DOI: 10.4103/atm.atm_155_24.


Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65 945 individual patients.

Waeijen-Smit K, Crutsen M, Keene S, Miravitlles M, Crisafulli E, Torres A ERJ Open Res. 2024; 10(1).

PMID: 38410700 PMC: 10895439. DOI: 10.1183/23120541.00838-2023.


Predictors of Readmission, for Patients with Chronic Obstructive Pulmonary Disease (COPD) - A Systematic Review.

Chow R, So O, Im J, Chapman K, Orchanian-Cheff A, Gershon A Int J Chron Obstruct Pulmon Dis. 2023; 18:2581-2617.

PMID: 38022828 PMC: 10664718. DOI: 10.2147/COPD.S418295.


Time-Updated Phenotypic Guidance of Corticosteroids and Antibiotics in COPD: Rationale, Perspective and a Proposed Method.

Jordan A, Sivapalan P, Romer V, Jensen J Biomedicines. 2023; 11(5).

PMID: 37239067 PMC: 10216322. DOI: 10.3390/biomedicines11051395.